Literature DB >> 25677925

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

Thomas Aparicio1, Benjamin Linot2, Karine Le Malicot3, Olivier Bouché4, Valérie Boige5, Eric François6, Francois Ghiringhelli7, Jean-Louis Legoux8, Meher Ben Abdelghani9, Jean-Marc Phelip10, Roger Faroux11, Laetitia Dahan12, Julien Taieb13, Laurent Bedenne14.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25677925     DOI： 10.1016/j.dld.2015.01.146

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


× No keyword cloud information.
  3 in total

Review 1.  Maintenance therapy for colorectal cancer: which regimen and which patients?

Authors:  Sameh Mikhail; Tanios Bekaii-Saab
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 2.  Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.

Authors:  Mateusz Kciuk; Beata Marciniak; Renata Kontek
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

3.  Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer.

Authors:  Adrien Guilloteau; Michal Abrahamowicz; Olayide Boussari; Valérie Jooste; Thomas Aparicio; Catherine Quantin; Karine Le Malicot; Christine Binquet
Journal:  BMC Med Res Methodol       Date:  2021-01-09       Impact factor: 4.615
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.